The bacterial genotoxin colibactin promotes colon tumor growth by modifying the tumor microenvironment Original paper

What was reviewed?

This article addendum reviewed and extended prior work showing that colibactin-producing (pks-positive) Escherichia coli can promote colon tumor growth by reshaping the tumor microenvironment, not just by causing DNA damage or inflammation. The authors focused on a “promotion” model in which brief bacterial contact with a small fraction of malignant cells triggers cellular senescence and a senescence-associated secretory phenotype that releases growth factors capable of stimulating proliferation in nearby, uninfected tumor cells, thereby sustaining tumor expansion.

Who was reviewed?

The paper discussed evidence from mouse xenograft experiments using human intestinal epithelial tumor cells, from multiple human intestinal epithelial cell lines studied in vitro, and from a chemically induced AOM/DSS colorectal cancer mouse model colonized with a clinical pks-positive E. coli strain and its matched pks-deficient mutant. It also reviewed supporting observations in human colorectal cancer biopsies that were colonized by pks-positive E. coli versus pks-negative E. coli, using these clinical samples to confirm that the same molecular “senescence and growth-factor” signals appear in human disease contexts.

What were the most important findings?

The key finding was that pks-positive E. coli can increase tumor growth through an indirect, paracrine mechanism driven by senescence and growth-factor release. In xenografts, a single short exposure to pks-positive bacteria increased tumor growth and proliferation markers when bacteria contacted tumors at a lower bacteria-to-tumor-cell ratio, while higher exposure pushed tumors toward growth suppression consistent with widespread arrest, reinforcing that dose and accessibility determine outcome. Infected epithelial cells developed classic senescence features and then produced a secretory program enriched in growth factors, with HGF emerging as a central mediator because blocking HGF signaling removed the pro-proliferative effect of conditioned media and reduced xenograft growth. Mechanistically, the authors linked senescence induction to altered p53 SUMOylation driven by a regulatory cascade in which colibactin-associated DNA damage increased c-Myc, which raised miR-20a-5p, which suppressed SENP1, leading to increased SUMO-conjugated p53 and senescence. In the AOM/DSS model and in human colorectal cancer biopsies colonized by pks-positive E. coli, tumors showed higher DNA damage and senescence-associated signals along with increased HGF pathway activation and lower SENP1-expressing cells, supporting that this pathway operates in vivo and can mark a microbiome-linked tumor-promoting niche.

What are the greatest implications of this study/ review?

This work reframes the microbiome signature “mucosa-associated pks-positive E. coli” as a driver of tumor promotion through microenvironment remodeling, meaning clinicians should consider colibactin exposure as a factor that can accelerate tumor progression even when only a subset of cells directly contacts bacteria. It also suggests a practical therapeutic logic: targeting colibactin production or interrupting downstream effectors of the senescence secretory program—especially HGF pathway signaling—could reduce protumor growth-factor pressure without requiring broad microbiome eradication. Finally, it implies that biomarkers such as miR-20a-5p, reduced SENP1, senescence markers, and HGF activation may help identify colibactin-linked tumors and stratify patients for adjunct approaches that address microbiota-associated promotion alongside standard oncologic care.